News

February 21, 2024

Elicera Therapeutics publishes prospectus in connection with rights issue of units

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera invites to investor meetings on February 28[th] and 29[th] 2024

Regulatory Press Release
Press Release
News
Read more
February 13, 2024

Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023

Regulatory Press Release
Press Release
News
Read more
February 9, 2024

Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

Elicera’s Board of Directors proposes a rights issue of units of approximately SEK 64 million

Regulatory Press Release
Press Release
News
Read more
January 17, 2024

Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON

Regulatory Press Release
Press Release
News
Read more
January 9, 2024

Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application

Regulatory Press Release
Press Release
News
Read more
November 30, 2023

Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ)

Regulatory Press Release
Press Release
News
Read more
November 14, 2023

Elicera Therapeutics AB (publ) Interim Report January 1 – September 30, 2023

Regulatory Press Release
Press Release
News
Read more
October 31, 2023

Nomination Committee for Elicera therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
September 8, 2023

Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform

Regulatory Press Release
Press Release
News
Read more
August 29, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023

Regulatory Press Release
Press Release
News
Read more
August 10, 2023

Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program

Regulatory Press Release
Press Release
News
Read more
July 11, 2023

Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform

Regulatory Press Release
Press Release
News
Read more
May 16, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023

Regulatory Press Release
Press Release
News
Read more
April 28, 2023

Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study)

Regulatory Press Release
Press Release
News
Read more
April 17, 2023

Elicera Therapeutics publishes the annual report for 2022

Regulatory Press Release
Press Release
News
Read more
March 6, 2023

Erik Penser Bank initiates coverage on Elicera Therapeutics

Regulatory Press Release
Press Release
News
Read more
March 1, 2023

Elicera Therapeutics hires Erik Penser Bank as market maker

Regulatory Press Release
Press Release
News
Read more
February 17, 2023

Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022

Regulatory Press Release
Press Release
News
Read more
February 7, 2023

Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives

Regulatory Press Release
Press Release
News
Read more
January 26, 2023

Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 23, 2023

Elicera Therapeutics continues phase I/IIa study with oncolytic virus as planned, following safety review in cohort 3

Regulatory Press Release
Press Release
News
Read more
December 7, 2022

Elicera Therapeutics reports additional signals of clinical activity in patients treated for neuroendocrine tumors in the ELC-100 study at the Oncolytic Virotherapy Summit in Boston

Regulatory Press Release
Press Release
News
Read more
November 18, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2022

Regulatory Press Release
Press Release
News
Read more
November 16, 2022

Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support CAR T research

Regulatory Press Release
Press Release
News
Read more
November 3, 2022

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 18, 2022

Elicera Therapeutics enters first international collaboration involving the iTANK platform with a Spanish research institution

Regulatory Press Release
Press Release
News
Read more
October 12, 2022

Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy

Regulatory Press Release
Press Release
News
Read more
September 7, 2022

LifeScientist interviews Di Yu

Regulatory Press Release
Press Release
News
Read more
August 31, 2022

Oncology in Sweden publishes an article by Magnus Essand on Elicera's iTANK platform and upcoming clinical study

Regulatory Press Release
Press Release
News
Read more
August 22, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2022

Regulatory Press Release
Press Release
News
Read more
August 12, 2022

Elicera Therapeutics announces participation in several industry and partnering conferences

Regulatory Press Release
Press Release
News
Read more
June 2, 2022

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Interviews with Magnus Essand and Gunilla Enblad at SWECARNET's education day April 27

Regulatory Press Release
Press Release
News
Read more
April 26, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory Press Release
Press Release
News
Read more
April 10, 2022

Upsala Nya Tidning writes about Elicera's research and upcoming clinical studies

Regulatory Press Release
Press Release
News
Read more
April 7, 2022

Nordic Life Science News writes about the iTANK-publication

Regulatory Press Release
Press Release
News
Read more
April 6, 2022

Biostock makes a video interview with CSO, professor Magnus Essand, on the iTANK, publication.

Regulatory Press Release
Press Release
News
Read more
April 4, 2022

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
March 1, 2022

Elicera featured in Life Science Sweden's perspective on CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
February 24, 2022

Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022

Regulatory Press Release
Press Release
News
Read more
February 4, 2022

Elicera Therapeutics publishes annual report for 2021

Regulatory Press Release
Press Release
News
Read more
January 25, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory Press Release
Press Release
News
Read more
January 20, 2022

Interview and summary of 2021 in Biostock

Regulatory Press Release
Press Release
News
Read more
January 19, 2022

Elicera in Nordic Life Science - Vinnova grant

Regulatory Press Release
Press Release
News
Read more
January 18, 2022

Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process

Regulatory Press Release
Press Release
News
Read more
January 14, 2022

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Nordic Life Science News writes about Elicera's patent acquisition from Immunicum

Regulatory Press Release
Press Release
News
Read more
December 15, 2021

Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201

Regulatory Press Release
Press Release
News
Read more
November 18, 2021

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory Press Release
Press Release
News
Read more
November 9, 2021

Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy

Regulatory Press Release
Press Release
News
Read more
November 4, 2021

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 22, 2021

Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Nordic Life Science News

Regulatory Press Release
Press Release
News
Read more
October 5, 2021

Elicera Therapeutics announces participation in several industry and investor meetings in October and November

Regulatory Press Release
Press Release
News
Read more
September 13, 2021

Elicera Therapeutics will present the iTANK platform orally at ESGCT Collaborative Virtual Congress and PEGS Europe

Regulatory Press Release
Press Release
News
Read more
August 20, 2021

Interim Report Elicera Therapeutics AB January – June 2021

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics' board and management buy shares

Regulatory Press Release
Press Release
News
Read more
June 24, 2021

Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus

Regulatory Press Release
Press Release
News
Read more
June 10, 2021

Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 9, 2021

Elicera Therapeutics' new issue heavily oversubscribed

Regulatory Press Release
Press Release
News
Read more
June 4, 2021

Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 3, 2021

CEO-interview by Nyhetsbyrån Direkt

Regulatory Press Release
Press Release
News
Read more
May 31, 2021

Article in "Forskning och framsteg"

Regulatory Press Release
Press Release
News
Read more
May 24, 2021

Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
May 18, 2021

Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.

Regulatory Press Release
Press Release
News
Read more
May 17, 2021

Company presentation at "Aktiedagen Göteborg".

Regulatory Press Release
Press Release
News
Read more
April 27, 2021

Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
April 15, 2021

Biostock writes about Elicera and CAR T-cells

Regulatory Press Release
Press Release
News
Read more
March 22, 2021

Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera Therapeutics recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 8, 2021

Elicera Therapeutics invitation to company presentation (in Swedish)

Regulatory Press Release
Press Release
News
Read more
October 20, 2020

Daily Mail writes about Elicera

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing

Regulatory Press Release
Press Release
News
Read more
July 15, 2020

Immuno-Oncology News writes about Elicera's CAR T-cell program

Regulatory Press Release
Press Release
News
Read more
July 6, 2020

Financial Times writes about Elicera

Regulatory Press Release
Press Release
News
Read more
June 3, 2020

Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed

Regulatory Press Release
Press Release
News
Read more
April 23, 2020

Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100

Regulatory Press Release
Press Release
News
Read more
April 2, 2020

Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers

Regulatory Press Release
Press Release
News
Read more
January 10, 2020

Funding from the Sjöberg Foundation

Regulatory Press Release
Press Release
News
Read more
November 13, 2019

Funding by the Swedish Cancer Society

Regulatory Press Release
Press Release
News
Read more
March 2, 2018

Status update by Uppsala University on the clinical phase I/II-study in NET

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

The Medical Journal writes about a clinical study

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

Swedish Public Radio interviews Professor Magnus Essand

Regulatory Press Release
Press Release
News
Read more
October 27, 2014

Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)

Regulatory Press Release
Press Release
News
Read more
June 15, 2013

Successful crowdfunding

Regulatory Press Release
Press Release
News
Read more
February 21, 2024

Elicera Therapeutics publishes prospectus in connection with rights issue of units

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera invites to investor meetings on February 28[th] and 29[th] 2024

Regulatory Press Release
Press Release
News
Read more
February 13, 2024

Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023

Regulatory Press Release
Press Release
News
Read more
February 9, 2024

Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

Elicera’s Board of Directors proposes a rights issue of units of approximately SEK 64 million

Regulatory Press Release
Press Release
News
Read more
January 17, 2024

Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON

Regulatory Press Release
Press Release
News
Read more
January 9, 2024

Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application

Regulatory Press Release
Press Release
News
Read more
November 30, 2023

Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ)

Regulatory Press Release
Press Release
News
Read more
November 14, 2023

Elicera Therapeutics AB (publ) Interim Report January 1 – September 30, 2023

Regulatory Press Release
Press Release
News
Read more
October 31, 2023

Nomination Committee for Elicera therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
September 8, 2023

Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform

Regulatory Press Release
Press Release
News
Read more
August 29, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023

Regulatory Press Release
Press Release
News
Read more
August 10, 2023

Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program

Regulatory Press Release
Press Release
News
Read more
July 11, 2023

Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform

Regulatory Press Release
Press Release
News
Read more
May 16, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023

Regulatory Press Release
Press Release
News
Read more
April 28, 2023

Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study)

Regulatory Press Release
Press Release
News
Read more
April 17, 2023

Elicera Therapeutics publishes the annual report for 2022

Regulatory Press Release
Press Release
News
Read more
March 6, 2023

Erik Penser Bank initiates coverage on Elicera Therapeutics

Regulatory Press Release
Press Release
News
Read more
March 1, 2023

Elicera Therapeutics hires Erik Penser Bank as market maker

Regulatory Press Release
Press Release
News
Read more
February 17, 2023

Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022

Regulatory Press Release
Press Release
News
Read more
February 7, 2023

Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives

Regulatory Press Release
Press Release
News
Read more
January 26, 2023

Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 23, 2023

Elicera Therapeutics continues phase I/IIa study with oncolytic virus as planned, following safety review in cohort 3

Regulatory Press Release
Press Release
News
Read more
December 7, 2022

Elicera Therapeutics reports additional signals of clinical activity in patients treated for neuroendocrine tumors in the ELC-100 study at the Oncolytic Virotherapy Summit in Boston

Regulatory Press Release
Press Release
News
Read more
November 18, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2022

Regulatory Press Release
Press Release
News
Read more
November 16, 2022

Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support CAR T research

Regulatory Press Release
Press Release
News
Read more
November 3, 2022

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 18, 2022

Elicera Therapeutics enters first international collaboration involving the iTANK platform with a Spanish research institution

Regulatory Press Release
Press Release
News
Read more
October 12, 2022

Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy

Regulatory Press Release
Press Release
News
Read more
September 7, 2022

LifeScientist interviews Di Yu

Regulatory Press Release
Press Release
News
Read more
August 31, 2022

Oncology in Sweden publishes an article by Magnus Essand on Elicera's iTANK platform and upcoming clinical study

Regulatory Press Release
Press Release
News
Read more
August 22, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2022

Regulatory Press Release
Press Release
News
Read more
August 12, 2022

Elicera Therapeutics announces participation in several industry and partnering conferences

Regulatory Press Release
Press Release
News
Read more
June 2, 2022

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Interviews with Magnus Essand and Gunilla Enblad at SWECARNET's education day April 27

Regulatory Press Release
Press Release
News
Read more
April 26, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory Press Release
Press Release
News
Read more
April 10, 2022

Upsala Nya Tidning writes about Elicera's research and upcoming clinical studies

Regulatory Press Release
Press Release
News
Read more
April 7, 2022

Nordic Life Science News writes about the iTANK-publication

Regulatory Press Release
Press Release
News
Read more
April 6, 2022

Biostock makes a video interview with CSO, professor Magnus Essand, on the iTANK, publication.

Regulatory Press Release
Press Release
News
Read more
April 4, 2022

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
March 1, 2022

Elicera featured in Life Science Sweden's perspective on CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
February 24, 2022

Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022

Regulatory Press Release
Press Release
News
Read more
February 4, 2022

Elicera Therapeutics publishes annual report for 2021

Regulatory Press Release
Press Release
News
Read more
January 25, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory Press Release
Press Release
News
Read more
January 20, 2022

Interview and summary of 2021 in Biostock

Regulatory Press Release
Press Release
News
Read more
January 19, 2022

Elicera in Nordic Life Science - Vinnova grant

Regulatory Press Release
Press Release
News
Read more
January 18, 2022

Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process

Regulatory Press Release
Press Release
News
Read more
January 14, 2022

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Nordic Life Science News writes about Elicera's patent acquisition from Immunicum

Regulatory Press Release
Press Release
News
Read more
December 15, 2021

Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201

Regulatory Press Release
Press Release
News
Read more
November 18, 2021

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory Press Release
Press Release
News
Read more
November 9, 2021

Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy

Regulatory Press Release
Press Release
News
Read more
November 4, 2021

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 22, 2021

Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Nordic Life Science News

Regulatory Press Release
Press Release
News
Read more
October 5, 2021

Elicera Therapeutics announces participation in several industry and investor meetings in October and November

Regulatory Press Release
Press Release
News
Read more
September 13, 2021

Elicera Therapeutics will present the iTANK platform orally at ESGCT Collaborative Virtual Congress and PEGS Europe

Regulatory Press Release
Press Release
News
Read more
August 20, 2021

Interim Report Elicera Therapeutics AB January – June 2021

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics' board and management buy shares

Regulatory Press Release
Press Release
News
Read more
June 24, 2021

Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus

Regulatory Press Release
Press Release
News
Read more
June 10, 2021

Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 9, 2021

Elicera Therapeutics' new issue heavily oversubscribed

Regulatory Press Release
Press Release
News
Read more
June 4, 2021

Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 3, 2021

CEO-interview by Nyhetsbyrån Direkt

Regulatory Press Release
Press Release
News
Read more
May 31, 2021

Article in "Forskning och framsteg"

Regulatory Press Release
Press Release
News
Read more
May 24, 2021

Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
May 18, 2021

Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.

Regulatory Press Release
Press Release
News
Read more
May 17, 2021

Company presentation at "Aktiedagen Göteborg".

Regulatory Press Release
Press Release
News
Read more
April 27, 2021

Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
April 15, 2021

Biostock writes about Elicera and CAR T-cells

Regulatory Press Release
Press Release
News
Read more
March 22, 2021

Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera Therapeutics recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 8, 2021

Elicera Therapeutics invitation to company presentation (in Swedish)

Regulatory Press Release
Press Release
News
Read more
October 20, 2020

Daily Mail writes about Elicera

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing

Regulatory Press Release
Press Release
News
Read more
July 15, 2020

Immuno-Oncology News writes about Elicera's CAR T-cell program

Regulatory Press Release
Press Release
News
Read more
July 6, 2020

Financial Times writes about Elicera

Regulatory Press Release
Press Release
News
Read more
June 3, 2020

Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed

Regulatory Press Release
Press Release
News
Read more
April 23, 2020

Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100

Regulatory Press Release
Press Release
News
Read more
April 2, 2020

Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers

Regulatory Press Release
Press Release
News
Read more
January 10, 2020

Funding from the Sjöberg Foundation

Regulatory Press Release
Press Release
News
Read more
November 13, 2019

Funding by the Swedish Cancer Society

Regulatory Press Release
Press Release
News
Read more
March 2, 2018

Status update by Uppsala University on the clinical phase I/II-study in NET

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

The Medical Journal writes about a clinical study

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

Swedish Public Radio interviews Professor Magnus Essand

Regulatory Press Release
Press Release
News
Read more
October 27, 2014

Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)

Regulatory Press Release
Press Release
News
Read more
June 15, 2013

Successful crowdfunding

Regulatory Press Release
Press Release
News
Read more
February 21, 2024

Elicera Therapeutics publishes prospectus in connection with rights issue of units

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera invites to investor meetings on February 28[th] and 29[th] 2024

Regulatory Press Release
Press Release
News
Read more
February 13, 2024

Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023

Regulatory Press Release
Press Release
News
Read more
February 9, 2024

Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

Elicera’s Board of Directors proposes a rights issue of units of approximately SEK 64 million

Regulatory Press Release
Press Release
News
Read more
January 17, 2024

Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON

Regulatory Press Release
Press Release
News
Read more
January 9, 2024

Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application

Regulatory Press Release
Press Release
News
Read more
November 30, 2023

Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ)

Regulatory Press Release
Press Release
News
Read more
November 14, 2023

Elicera Therapeutics AB (publ) Interim Report January 1 – September 30, 2023

Regulatory Press Release
Press Release
News
Read more
October 31, 2023

Nomination Committee for Elicera therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
September 8, 2023

Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform

Regulatory Press Release
Press Release
News
Read more
August 29, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023

Regulatory Press Release
Press Release
News
Read more
August 10, 2023

Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program

Regulatory Press Release
Press Release
News
Read more
July 11, 2023

Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform

Regulatory Press Release
Press Release
News
Read more
May 16, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023

Regulatory Press Release
Press Release
News
Read more
April 28, 2023

Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study)

Regulatory Press Release
Press Release
News
Read more
April 17, 2023

Elicera Therapeutics publishes the annual report for 2022

Regulatory Press Release
Press Release
News
Read more
March 6, 2023

Erik Penser Bank initiates coverage on Elicera Therapeutics

Regulatory Press Release
Press Release
News
Read more
March 1, 2023

Elicera Therapeutics hires Erik Penser Bank as market maker

Regulatory Press Release
Press Release
News
Read more
February 17, 2023

Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022

Regulatory Press Release
Press Release
News
Read more
February 7, 2023

Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives

Regulatory Press Release
Press Release
News
Read more
January 26, 2023

Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 23, 2023

Elicera Therapeutics continues phase I/IIa study with oncolytic virus as planned, following safety review in cohort 3

Regulatory Press Release
Press Release
News
Read more
December 7, 2022

Elicera Therapeutics reports additional signals of clinical activity in patients treated for neuroendocrine tumors in the ELC-100 study at the Oncolytic Virotherapy Summit in Boston

Regulatory Press Release
Press Release
News
Read more
November 18, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2022

Regulatory Press Release
Press Release
News
Read more
November 16, 2022

Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support CAR T research

Regulatory Press Release
Press Release
News
Read more
November 3, 2022

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 18, 2022

Elicera Therapeutics enters first international collaboration involving the iTANK platform with a Spanish research institution

Regulatory Press Release
Press Release
News
Read more
October 12, 2022

Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy

Regulatory Press Release
Press Release
News
Read more
September 7, 2022

LifeScientist interviews Di Yu

Regulatory Press Release
Press Release
News
Read more
August 31, 2022

Oncology in Sweden publishes an article by Magnus Essand on Elicera's iTANK platform and upcoming clinical study

Regulatory Press Release
Press Release
News
Read more
August 22, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2022

Regulatory Press Release
Press Release
News
Read more
August 12, 2022

Elicera Therapeutics announces participation in several industry and partnering conferences

Regulatory Press Release
Press Release
News
Read more
June 2, 2022

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Interviews with Magnus Essand and Gunilla Enblad at SWECARNET's education day April 27

Regulatory Press Release
Press Release
News
Read more
April 26, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory Press Release
Press Release
News
Read more
April 10, 2022

Upsala Nya Tidning writes about Elicera's research and upcoming clinical studies

Regulatory Press Release
Press Release
News
Read more
April 7, 2022

Nordic Life Science News writes about the iTANK-publication

Regulatory Press Release
Press Release
News
Read more
April 6, 2022

Biostock makes a video interview with CSO, professor Magnus Essand, on the iTANK, publication.

Regulatory Press Release
Press Release
News
Read more
April 4, 2022

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
March 1, 2022

Elicera featured in Life Science Sweden's perspective on CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
February 24, 2022

Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022

Regulatory Press Release
Press Release
News
Read more
February 4, 2022

Elicera Therapeutics publishes annual report for 2021

Regulatory Press Release
Press Release
News
Read more
January 25, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory Press Release
Press Release
News
Read more
January 20, 2022

Interview and summary of 2021 in Biostock

Regulatory Press Release
Press Release
News
Read more
January 19, 2022

Elicera in Nordic Life Science - Vinnova grant

Regulatory Press Release
Press Release
News
Read more
January 18, 2022

Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process

Regulatory Press Release
Press Release
News
Read more
January 14, 2022

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Nordic Life Science News writes about Elicera's patent acquisition from Immunicum

Regulatory Press Release
Press Release
News
Read more
December 15, 2021

Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201

Regulatory Press Release
Press Release
News
Read more
November 18, 2021

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory Press Release
Press Release
News
Read more
November 9, 2021

Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy

Regulatory Press Release
Press Release
News
Read more
November 4, 2021

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 22, 2021

Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Nordic Life Science News

Regulatory Press Release
Press Release
News
Read more
October 5, 2021

Elicera Therapeutics announces participation in several industry and investor meetings in October and November

Regulatory Press Release
Press Release
News
Read more
September 13, 2021

Elicera Therapeutics will present the iTANK platform orally at ESGCT Collaborative Virtual Congress and PEGS Europe

Regulatory Press Release
Press Release
News
Read more
August 20, 2021

Interim Report Elicera Therapeutics AB January – June 2021

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics' board and management buy shares

Regulatory Press Release
Press Release
News
Read more
June 24, 2021

Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus

Regulatory Press Release
Press Release
News
Read more
June 10, 2021

Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 9, 2021

Elicera Therapeutics' new issue heavily oversubscribed

Regulatory Press Release
Press Release
News
Read more
June 4, 2021

Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 3, 2021

CEO-interview by Nyhetsbyrån Direkt

Regulatory Press Release
Press Release
News
Read more
May 31, 2021

Article in "Forskning och framsteg"

Regulatory Press Release
Press Release
News
Read more
May 24, 2021

Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
May 18, 2021

Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.

Regulatory Press Release
Press Release
News
Read more
May 17, 2021

Company presentation at "Aktiedagen Göteborg".

Regulatory Press Release
Press Release
News
Read more
April 27, 2021

Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
April 15, 2021

Biostock writes about Elicera and CAR T-cells

Regulatory Press Release
Press Release
News
Read more
March 22, 2021

Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera Therapeutics recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 8, 2021

Elicera Therapeutics invitation to company presentation (in Swedish)

Regulatory Press Release
Press Release
News
Read more
October 20, 2020

Daily Mail writes about Elicera

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing

Regulatory Press Release
Press Release
News
Read more
July 15, 2020

Immuno-Oncology News writes about Elicera's CAR T-cell program

Regulatory Press Release
Press Release
News
Read more
July 6, 2020

Financial Times writes about Elicera

Regulatory Press Release
Press Release
News
Read more
June 3, 2020

Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed

Regulatory Press Release
Press Release
News
Read more
April 23, 2020

Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100

Regulatory Press Release
Press Release
News
Read more
April 2, 2020

Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers

Regulatory Press Release
Press Release
News
Read more
January 10, 2020

Funding from the Sjöberg Foundation

Regulatory Press Release
Press Release
News
Read more
November 13, 2019

Funding by the Swedish Cancer Society

Regulatory Press Release
Press Release
News
Read more
March 2, 2018

Status update by Uppsala University on the clinical phase I/II-study in NET

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

The Medical Journal writes about a clinical study

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

Swedish Public Radio interviews Professor Magnus Essand

Regulatory Press Release
Press Release
News
Read more
October 27, 2014

Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)

Regulatory Press Release
Press Release
News
Read more
June 15, 2013

Successful crowdfunding

Regulatory Press Release
Press Release
News
Read more
February 21, 2024

Elicera Therapeutics publishes prospectus in connection with rights issue of units

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera invites to investor meetings on February 28[th] and 29[th] 2024

Regulatory Press Release
Press Release
News
Read more
February 13, 2024

Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023

Regulatory Press Release
Press Release
News
Read more
February 9, 2024

Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

Elicera’s Board of Directors proposes a rights issue of units of approximately SEK 64 million

Regulatory Press Release
Press Release
News
Read more
January 17, 2024

Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON

Regulatory Press Release
Press Release
News
Read more
January 9, 2024

Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application

Regulatory Press Release
Press Release
News
Read more
November 30, 2023

Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ)

Regulatory Press Release
Press Release
News
Read more
November 14, 2023

Elicera Therapeutics AB (publ) Interim Report January 1 – September 30, 2023

Regulatory Press Release
Press Release
News
Read more
October 31, 2023

Nomination Committee for Elicera therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
September 8, 2023

Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform

Regulatory Press Release
Press Release
News
Read more
August 29, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023

Regulatory Press Release
Press Release
News
Read more
August 10, 2023

Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program

Regulatory Press Release
Press Release
News
Read more
July 11, 2023

Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform

Regulatory Press Release
Press Release
News
Read more
May 16, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023

Regulatory Press Release
Press Release
News
Read more
April 28, 2023

Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study)

Regulatory Press Release
Press Release
News
Read more
April 17, 2023

Elicera Therapeutics publishes the annual report for 2022

Regulatory Press Release
Press Release
News
Read more
March 6, 2023

Erik Penser Bank initiates coverage on Elicera Therapeutics

Regulatory Press Release
Press Release
News
Read more
March 1, 2023

Elicera Therapeutics hires Erik Penser Bank as market maker

Regulatory Press Release
Press Release
News
Read more
February 17, 2023

Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022

Regulatory Press Release
Press Release
News
Read more
February 7, 2023

Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives

Regulatory Press Release
Press Release
News
Read more
January 26, 2023

Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 23, 2023

Elicera Therapeutics continues phase I/IIa study with oncolytic virus as planned, following safety review in cohort 3

Regulatory Press Release
Press Release
News
Read more
December 7, 2022

Elicera Therapeutics reports additional signals of clinical activity in patients treated for neuroendocrine tumors in the ELC-100 study at the Oncolytic Virotherapy Summit in Boston

Regulatory Press Release
Press Release
News
Read more
November 18, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2022

Regulatory Press Release
Press Release
News
Read more
November 16, 2022

Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support CAR T research

Regulatory Press Release
Press Release
News
Read more
November 3, 2022

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 18, 2022

Elicera Therapeutics enters first international collaboration involving the iTANK platform with a Spanish research institution

Regulatory Press Release
Press Release
News
Read more
October 12, 2022

Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy

Regulatory Press Release
Press Release
News
Read more
September 7, 2022

LifeScientist interviews Di Yu

Regulatory Press Release
Press Release
News
Read more
August 31, 2022

Oncology in Sweden publishes an article by Magnus Essand on Elicera's iTANK platform and upcoming clinical study

Regulatory Press Release
Press Release
News
Read more
August 22, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2022

Regulatory Press Release
Press Release
News
Read more
August 12, 2022

Elicera Therapeutics announces participation in several industry and partnering conferences

Regulatory Press Release
Press Release
News
Read more
June 2, 2022

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Interviews with Magnus Essand and Gunilla Enblad at SWECARNET's education day April 27

Regulatory Press Release
Press Release
News
Read more
April 26, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory Press Release
Press Release
News
Read more
April 10, 2022

Upsala Nya Tidning writes about Elicera's research and upcoming clinical studies

Regulatory Press Release
Press Release
News
Read more
April 7, 2022

Nordic Life Science News writes about the iTANK-publication

Regulatory Press Release
Press Release
News
Read more
April 6, 2022

Biostock makes a video interview with CSO, professor Magnus Essand, on the iTANK, publication.

Regulatory Press Release
Press Release
News
Read more
April 4, 2022

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
March 1, 2022

Elicera featured in Life Science Sweden's perspective on CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
February 24, 2022

Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022

Regulatory Press Release
Press Release
News
Read more
February 4, 2022

Elicera Therapeutics publishes annual report for 2021

Regulatory Press Release
Press Release
News
Read more
January 25, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory Press Release
Press Release
News
Read more
January 20, 2022

Interview and summary of 2021 in Biostock

Regulatory Press Release
Press Release
News
Read more
January 19, 2022

Elicera in Nordic Life Science - Vinnova grant

Regulatory Press Release
Press Release
News
Read more
January 18, 2022

Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process

Regulatory Press Release
Press Release
News
Read more
January 14, 2022

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Nordic Life Science News writes about Elicera's patent acquisition from Immunicum

Regulatory Press Release
Press Release
News
Read more
December 15, 2021

Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201

Regulatory Press Release
Press Release
News
Read more
November 18, 2021

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory Press Release
Press Release
News
Read more
November 9, 2021

Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy

Regulatory Press Release
Press Release
News
Read more
November 4, 2021

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 22, 2021

Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Nordic Life Science News

Regulatory Press Release
Press Release
News
Read more
October 5, 2021

Elicera Therapeutics announces participation in several industry and investor meetings in October and November

Regulatory Press Release
Press Release
News
Read more
September 13, 2021

Elicera Therapeutics will present the iTANK platform orally at ESGCT Collaborative Virtual Congress and PEGS Europe

Regulatory Press Release
Press Release
News
Read more
August 20, 2021

Interim Report Elicera Therapeutics AB January – June 2021

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics' board and management buy shares

Regulatory Press Release
Press Release
News
Read more
June 24, 2021

Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus

Regulatory Press Release
Press Release
News
Read more
June 10, 2021

Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 9, 2021

Elicera Therapeutics' new issue heavily oversubscribed

Regulatory Press Release
Press Release
News
Read more
June 4, 2021

Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 3, 2021

CEO-interview by Nyhetsbyrån Direkt

Regulatory Press Release
Press Release
News
Read more
May 31, 2021

Article in "Forskning och framsteg"

Regulatory Press Release
Press Release
News
Read more
May 24, 2021

Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
May 18, 2021

Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.

Regulatory Press Release
Press Release
News
Read more
May 17, 2021

Company presentation at "Aktiedagen Göteborg".

Regulatory Press Release
Press Release
News
Read more
April 27, 2021

Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
April 15, 2021

Biostock writes about Elicera and CAR T-cells

Regulatory Press Release
Press Release
News
Read more
March 22, 2021

Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera Therapeutics recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 8, 2021

Elicera Therapeutics invitation to company presentation (in Swedish)

Regulatory Press Release
Press Release
News
Read more
October 20, 2020

Daily Mail writes about Elicera

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing

Regulatory Press Release
Press Release
News
Read more
July 15, 2020

Immuno-Oncology News writes about Elicera's CAR T-cell program

Regulatory Press Release
Press Release
News
Read more
July 6, 2020

Financial Times writes about Elicera

Regulatory Press Release
Press Release
News
Read more
June 3, 2020

Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed

Regulatory Press Release
Press Release
News
Read more
April 23, 2020

Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100

Regulatory Press Release
Press Release
News
Read more
April 2, 2020

Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers

Regulatory Press Release
Press Release
News
Read more
January 10, 2020

Funding from the Sjöberg Foundation

Regulatory Press Release
Press Release
News
Read more
November 13, 2019

Funding by the Swedish Cancer Society

Regulatory Press Release
Press Release
News
Read more
March 2, 2018

Status update by Uppsala University on the clinical phase I/II-study in NET

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

The Medical Journal writes about a clinical study

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

Swedish Public Radio interviews Professor Magnus Essand

Regulatory Press Release
Press Release
News
Read more
October 27, 2014

Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)

Regulatory Press Release
Press Release
News
Read more
June 15, 2013

Successful crowdfunding

Regulatory Press Release
Press Release
News
Read more
February 21, 2024

Elicera Therapeutics publishes prospectus in connection with rights issue of units

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera invites to investor meetings on February 28[th] and 29[th] 2024

Regulatory Press Release
Press Release
News
Read more
February 13, 2024

Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023

Regulatory Press Release
Press Release
News
Read more
February 9, 2024

Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

Elicera’s Board of Directors proposes a rights issue of units of approximately SEK 64 million

Regulatory Press Release
Press Release
News
Read more
January 17, 2024

Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON

Regulatory Press Release
Press Release
News
Read more
January 9, 2024

Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application

Regulatory Press Release
Press Release
News
Read more
November 30, 2023

Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ)

Regulatory Press Release
Press Release
News
Read more
November 14, 2023

Elicera Therapeutics AB (publ) Interim Report January 1 – September 30, 2023

Regulatory Press Release
Press Release
News
Read more
October 31, 2023

Nomination Committee for Elicera therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
September 8, 2023

Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform

Regulatory Press Release
Press Release
News
Read more
August 29, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023

Regulatory Press Release
Press Release
News
Read more
August 10, 2023

Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program

Regulatory Press Release
Press Release
News
Read more
July 11, 2023

Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform

Regulatory Press Release
Press Release
News
Read more
May 16, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023

Regulatory Press Release
Press Release
News
Read more
April 28, 2023

Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study)

Regulatory Press Release
Press Release
News
Read more
April 17, 2023

Elicera Therapeutics publishes the annual report for 2022

Regulatory Press Release
Press Release
News
Read more
March 6, 2023

Erik Penser Bank initiates coverage on Elicera Therapeutics

Regulatory Press Release
Press Release
News
Read more
March 1, 2023

Elicera Therapeutics hires Erik Penser Bank as market maker

Regulatory Press Release
Press Release
News
Read more
February 17, 2023

Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022

Regulatory Press Release
Press Release
News
Read more
February 7, 2023

Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives

Regulatory Press Release
Press Release
News
Read more
January 26, 2023

Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 23, 2023

Elicera Therapeutics continues phase I/IIa study with oncolytic virus as planned, following safety review in cohort 3

Regulatory Press Release
Press Release
News
Read more
December 7, 2022

Elicera Therapeutics reports additional signals of clinical activity in patients treated for neuroendocrine tumors in the ELC-100 study at the Oncolytic Virotherapy Summit in Boston

Regulatory Press Release
Press Release
News
Read more
November 18, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2022

Regulatory Press Release
Press Release
News
Read more
November 16, 2022

Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support CAR T research

Regulatory Press Release
Press Release
News
Read more
November 3, 2022

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 18, 2022

Elicera Therapeutics enters first international collaboration involving the iTANK platform with a Spanish research institution

Regulatory Press Release
Press Release
News
Read more
October 12, 2022

Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy

Regulatory Press Release
Press Release
News
Read more
September 7, 2022

LifeScientist interviews Di Yu

Regulatory Press Release
Press Release
News
Read more
August 31, 2022

Oncology in Sweden publishes an article by Magnus Essand on Elicera's iTANK platform and upcoming clinical study

Regulatory Press Release
Press Release
News
Read more
August 22, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2022

Regulatory Press Release
Press Release
News
Read more
August 12, 2022

Elicera Therapeutics announces participation in several industry and partnering conferences

Regulatory Press Release
Press Release
News
Read more
June 2, 2022

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Interviews with Magnus Essand and Gunilla Enblad at SWECARNET's education day April 27

Regulatory Press Release
Press Release
News
Read more
April 26, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory Press Release
Press Release
News
Read more
April 10, 2022

Upsala Nya Tidning writes about Elicera's research and upcoming clinical studies

Regulatory Press Release
Press Release
News
Read more
April 7, 2022

Nordic Life Science News writes about the iTANK-publication

Regulatory Press Release
Press Release
News
Read more
April 6, 2022

Biostock makes a video interview with CSO, professor Magnus Essand, on the iTANK, publication.

Regulatory Press Release
Press Release
News
Read more
April 4, 2022

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
March 1, 2022

Elicera featured in Life Science Sweden's perspective on CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
February 24, 2022

Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022

Regulatory Press Release
Press Release
News
Read more
February 4, 2022

Elicera Therapeutics publishes annual report for 2021

Regulatory Press Release
Press Release
News
Read more
January 25, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory Press Release
Press Release
News
Read more
January 20, 2022

Interview and summary of 2021 in Biostock

Regulatory Press Release
Press Release
News
Read more
January 19, 2022

Elicera in Nordic Life Science - Vinnova grant

Regulatory Press Release
Press Release
News
Read more
January 18, 2022

Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process

Regulatory Press Release
Press Release
News
Read more
January 14, 2022

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Nordic Life Science News writes about Elicera's patent acquisition from Immunicum

Regulatory Press Release
Press Release
News
Read more
December 15, 2021

Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201

Regulatory Press Release
Press Release
News
Read more
November 18, 2021

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory Press Release
Press Release
News
Read more
November 9, 2021

Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy

Regulatory Press Release
Press Release
News
Read more
November 4, 2021

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 22, 2021

Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Nordic Life Science News

Regulatory Press Release
Press Release
News
Read more
October 5, 2021

Elicera Therapeutics announces participation in several industry and investor meetings in October and November

Regulatory Press Release
Press Release
News
Read more
September 13, 2021

Elicera Therapeutics will present the iTANK platform orally at ESGCT Collaborative Virtual Congress and PEGS Europe

Regulatory Press Release
Press Release
News
Read more
August 20, 2021

Interim Report Elicera Therapeutics AB January – June 2021

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics' board and management buy shares

Regulatory Press Release
Press Release
News
Read more
June 24, 2021

Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus

Regulatory Press Release
Press Release
News
Read more
June 10, 2021

Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 9, 2021

Elicera Therapeutics' new issue heavily oversubscribed

Regulatory Press Release
Press Release
News
Read more
June 4, 2021

Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 3, 2021

CEO-interview by Nyhetsbyrån Direkt

Regulatory Press Release
Press Release
News
Read more
May 31, 2021

Article in "Forskning och framsteg"

Regulatory Press Release
Press Release
News
Read more
May 24, 2021

Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
May 18, 2021

Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.

Regulatory Press Release
Press Release
News
Read more
May 17, 2021

Company presentation at "Aktiedagen Göteborg".

Regulatory Press Release
Press Release
News
Read more
April 27, 2021

Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
April 15, 2021

Biostock writes about Elicera and CAR T-cells

Regulatory Press Release
Press Release
News
Read more
March 22, 2021

Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera Therapeutics recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 8, 2021

Elicera Therapeutics invitation to company presentation (in Swedish)

Regulatory Press Release
Press Release
News
Read more
October 20, 2020

Daily Mail writes about Elicera

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing

Regulatory Press Release
Press Release
News
Read more
July 15, 2020

Immuno-Oncology News writes about Elicera's CAR T-cell program

Regulatory Press Release
Press Release
News
Read more
July 6, 2020

Financial Times writes about Elicera

Regulatory Press Release
Press Release
News
Read more
June 3, 2020

Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed

Regulatory Press Release
Press Release
News
Read more
April 23, 2020

Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100

Regulatory Press Release
Press Release
News
Read more
April 2, 2020

Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers

Regulatory Press Release
Press Release
News
Read more
January 10, 2020

Funding from the Sjöberg Foundation

Regulatory Press Release
Press Release
News
Read more
November 13, 2019

Funding by the Swedish Cancer Society

Regulatory Press Release
Press Release
News
Read more
March 2, 2018

Status update by Uppsala University on the clinical phase I/II-study in NET

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

The Medical Journal writes about a clinical study

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

Swedish Public Radio interviews Professor Magnus Essand

Regulatory Press Release
Press Release
News
Read more
October 27, 2014

Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)

Regulatory Press Release
Press Release
News
Read more
June 15, 2013

Successful crowdfunding

Regulatory Press Release
Press Release
News
Read more
February 21, 2024

Elicera Therapeutics publishes prospectus in connection with rights issue of units

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera invites to investor meetings on February 28[th] and 29[th] 2024

Regulatory Press Release
Press Release
News
Read more
February 13, 2024

Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023

Regulatory Press Release
Press Release
News
Read more
February 9, 2024

Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

Elicera’s Board of Directors proposes a rights issue of units of approximately SEK 64 million

Regulatory Press Release
Press Release
News
Read more
January 17, 2024

Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON

Regulatory Press Release
Press Release
News
Read more
January 9, 2024

Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application

Regulatory Press Release
Press Release
News
Read more
November 30, 2023

Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ)

Regulatory Press Release
Press Release
News
Read more
November 14, 2023

Elicera Therapeutics AB (publ) Interim Report January 1 – September 30, 2023

Regulatory Press Release
Press Release
News
Read more
October 31, 2023

Nomination Committee for Elicera therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
September 8, 2023

Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform

Regulatory Press Release
Press Release
News
Read more
August 29, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023

Regulatory Press Release
Press Release
News
Read more
August 10, 2023

Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program

Regulatory Press Release
Press Release
News
Read more
July 11, 2023

Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform

Regulatory Press Release
Press Release
News
Read more
May 16, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023

Regulatory Press Release
Press Release
News
Read more
April 28, 2023

Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study)

Regulatory Press Release
Press Release
News
Read more
April 17, 2023

Elicera Therapeutics publishes the annual report for 2022

Regulatory Press Release
Press Release
News
Read more
March 6, 2023

Erik Penser Bank initiates coverage on Elicera Therapeutics

Regulatory Press Release
Press Release
News
Read more
March 1, 2023

Elicera Therapeutics hires Erik Penser Bank as market maker

Regulatory Press Release
Press Release
News
Read more
February 17, 2023

Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022

Regulatory Press Release
Press Release
News
Read more
February 7, 2023

Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives

Regulatory Press Release
Press Release
News
Read more
January 26, 2023

Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 23, 2023

Elicera Therapeutics continues phase I/IIa study with oncolytic virus as planned, following safety review in cohort 3

Regulatory Press Release
Press Release
News
Read more
December 7, 2022

Elicera Therapeutics reports additional signals of clinical activity in patients treated for neuroendocrine tumors in the ELC-100 study at the Oncolytic Virotherapy Summit in Boston

Regulatory Press Release
Press Release
News
Read more
November 18, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2022

Regulatory Press Release
Press Release
News
Read more
November 16, 2022

Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support CAR T research

Regulatory Press Release
Press Release
News
Read more
November 3, 2022

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 18, 2022

Elicera Therapeutics enters first international collaboration involving the iTANK platform with a Spanish research institution

Regulatory Press Release
Press Release
News
Read more
October 12, 2022

Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy

Regulatory Press Release
Press Release
News
Read more
September 7, 2022

LifeScientist interviews Di Yu

Regulatory Press Release
Press Release
News
Read more
August 31, 2022

Oncology in Sweden publishes an article by Magnus Essand on Elicera's iTANK platform and upcoming clinical study

Regulatory Press Release
Press Release
News
Read more
August 22, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2022

Regulatory Press Release
Press Release
News
Read more
August 12, 2022

Elicera Therapeutics announces participation in several industry and partnering conferences

Regulatory Press Release
Press Release
News
Read more
June 2, 2022

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Interviews with Magnus Essand and Gunilla Enblad at SWECARNET's education day April 27

Regulatory Press Release
Press Release
News
Read more
April 26, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory Press Release
Press Release
News
Read more
April 10, 2022

Upsala Nya Tidning writes about Elicera's research and upcoming clinical studies

Regulatory Press Release
Press Release
News
Read more
April 7, 2022

Nordic Life Science News writes about the iTANK-publication

Regulatory Press Release
Press Release
News
Read more
April 6, 2022

Biostock makes a video interview with CSO, professor Magnus Essand, on the iTANK, publication.

Regulatory Press Release
Press Release
News
Read more
April 4, 2022

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
March 1, 2022

Elicera featured in Life Science Sweden's perspective on CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
February 24, 2022

Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022

Regulatory Press Release
Press Release
News
Read more
February 4, 2022

Elicera Therapeutics publishes annual report for 2021

Regulatory Press Release
Press Release
News
Read more
January 25, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory Press Release
Press Release
News
Read more
January 20, 2022

Interview and summary of 2021 in Biostock

Regulatory Press Release
Press Release
News
Read more
January 19, 2022

Elicera in Nordic Life Science - Vinnova grant

Regulatory Press Release
Press Release
News
Read more
January 18, 2022

Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process

Regulatory Press Release
Press Release
News
Read more
January 14, 2022

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Nordic Life Science News writes about Elicera's patent acquisition from Immunicum

Regulatory Press Release
Press Release
News
Read more
December 15, 2021

Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201

Regulatory Press Release
Press Release
News
Read more
November 18, 2021

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory Press Release
Press Release
News
Read more
November 9, 2021

Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy

Regulatory Press Release
Press Release
News
Read more
November 4, 2021

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 22, 2021

Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Nordic Life Science News

Regulatory Press Release
Press Release
News
Read more
October 5, 2021

Elicera Therapeutics announces participation in several industry and investor meetings in October and November

Regulatory Press Release
Press Release
News
Read more
September 13, 2021

Elicera Therapeutics will present the iTANK platform orally at ESGCT Collaborative Virtual Congress and PEGS Europe

Regulatory Press Release
Press Release
News
Read more
August 20, 2021

Interim Report Elicera Therapeutics AB January – June 2021

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics' board and management buy shares

Regulatory Press Release
Press Release
News
Read more
June 24, 2021

Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus

Regulatory Press Release
Press Release
News
Read more
June 10, 2021

Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 9, 2021

Elicera Therapeutics' new issue heavily oversubscribed

Regulatory Press Release
Press Release
News
Read more
June 4, 2021

Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 3, 2021

CEO-interview by Nyhetsbyrån Direkt

Regulatory Press Release
Press Release
News
Read more
May 31, 2021

Article in "Forskning och framsteg"

Regulatory Press Release
Press Release
News
Read more
May 24, 2021

Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
May 18, 2021

Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.

Regulatory Press Release
Press Release
News
Read more
May 17, 2021

Company presentation at "Aktiedagen Göteborg".

Regulatory Press Release
Press Release
News
Read more
April 27, 2021

Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
April 15, 2021

Biostock writes about Elicera and CAR T-cells

Regulatory Press Release
Press Release
News
Read more
March 22, 2021

Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera Therapeutics recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 8, 2021

Elicera Therapeutics invitation to company presentation (in Swedish)

Regulatory Press Release
Press Release
News
Read more
October 20, 2020

Daily Mail writes about Elicera

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing

Regulatory Press Release
Press Release
News
Read more
July 15, 2020

Immuno-Oncology News writes about Elicera's CAR T-cell program

Regulatory Press Release
Press Release
News
Read more
July 6, 2020

Financial Times writes about Elicera

Regulatory Press Release
Press Release
News
Read more
June 3, 2020

Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed

Regulatory Press Release
Press Release
News
Read more
April 23, 2020

Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100

Regulatory Press Release
Press Release
News
Read more
April 2, 2020

Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers

Regulatory Press Release
Press Release
News
Read more
January 10, 2020

Funding from the Sjöberg Foundation

Regulatory Press Release
Press Release
News
Read more
November 13, 2019

Funding by the Swedish Cancer Society

Regulatory Press Release
Press Release
News
Read more
March 2, 2018

Status update by Uppsala University on the clinical phase I/II-study in NET

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

The Medical Journal writes about a clinical study

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

Swedish Public Radio interviews Professor Magnus Essand

Regulatory Press Release
Press Release
News
Read more
October 27, 2014

Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)

Regulatory Press Release
Press Release
News
Read more
June 15, 2013

Successful crowdfunding

Regulatory Press Release
Press Release
News
Read more
February 21, 2024

Elicera Therapeutics publishes prospectus in connection with rights issue of units

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera invites to investor meetings on February 28[th] and 29[th] 2024

Regulatory Press Release
Press Release
News
Read more
February 13, 2024

Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023

Regulatory Press Release
Press Release
News
Read more
February 9, 2024

Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

Elicera’s Board of Directors proposes a rights issue of units of approximately SEK 64 million

Regulatory Press Release
Press Release
News
Read more
January 17, 2024

Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON

Regulatory Press Release
Press Release
News
Read more
January 9, 2024

Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application

Regulatory Press Release
Press Release
News
Read more
November 30, 2023

Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ)

Regulatory Press Release
Press Release
News
Read more
November 14, 2023

Elicera Therapeutics AB (publ) Interim Report January 1 – September 30, 2023

Regulatory Press Release
Press Release
News
Read more
October 31, 2023

Nomination Committee for Elicera therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
September 8, 2023

Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform

Regulatory Press Release
Press Release
News
Read more
August 29, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023

Regulatory Press Release
Press Release
News
Read more
August 10, 2023

Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program

Regulatory Press Release
Press Release
News
Read more
July 11, 2023

Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform

Regulatory Press Release
Press Release
News
Read more
May 16, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023

Regulatory Press Release
Press Release
News
Read more
April 28, 2023

Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study)

Regulatory Press Release
Press Release
News
Read more
April 17, 2023

Elicera Therapeutics publishes the annual report for 2022

Regulatory Press Release
Press Release
News
Read more
March 6, 2023

Erik Penser Bank initiates coverage on Elicera Therapeutics

Regulatory Press Release
Press Release
News
Read more
March 1, 2023

Elicera Therapeutics hires Erik Penser Bank as market maker

Regulatory Press Release
Press Release
News
Read more
February 17, 2023

Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022

Regulatory Press Release
Press Release
News
Read more
February 7, 2023

Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives

Regulatory Press Release
Press Release
News
Read more
January 26, 2023

Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 23, 2023

Elicera Therapeutics continues phase I/IIa study with oncolytic virus as planned, following safety review in cohort 3

Regulatory Press Release
Press Release
News
Read more
December 7, 2022

Elicera Therapeutics reports additional signals of clinical activity in patients treated for neuroendocrine tumors in the ELC-100 study at the Oncolytic Virotherapy Summit in Boston

Regulatory Press Release
Press Release
News
Read more
November 18, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2022

Regulatory Press Release
Press Release
News
Read more
November 16, 2022

Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support CAR T research

Regulatory Press Release
Press Release
News
Read more
November 3, 2022

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 18, 2022

Elicera Therapeutics enters first international collaboration involving the iTANK platform with a Spanish research institution

Regulatory Press Release
Press Release
News
Read more
October 12, 2022

Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy

Regulatory Press Release
Press Release
News
Read more
September 7, 2022

LifeScientist interviews Di Yu

Regulatory Press Release
Press Release
News
Read more
August 31, 2022

Oncology in Sweden publishes an article by Magnus Essand on Elicera's iTANK platform and upcoming clinical study

Regulatory Press Release
Press Release
News
Read more
August 22, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2022

Regulatory Press Release
Press Release
News
Read more
August 12, 2022

Elicera Therapeutics announces participation in several industry and partnering conferences

Regulatory Press Release
Press Release
News
Read more
June 2, 2022

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Interviews with Magnus Essand and Gunilla Enblad at SWECARNET's education day April 27

Regulatory Press Release
Press Release
News
Read more
April 26, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory Press Release
Press Release
News
Read more
April 10, 2022

Upsala Nya Tidning writes about Elicera's research and upcoming clinical studies

Regulatory Press Release
Press Release
News
Read more
April 7, 2022

Nordic Life Science News writes about the iTANK-publication

Regulatory Press Release
Press Release
News
Read more
April 6, 2022

Biostock makes a video interview with CSO, professor Magnus Essand, on the iTANK, publication.

Regulatory Press Release
Press Release
News
Read more
April 4, 2022

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
March 1, 2022

Elicera featured in Life Science Sweden's perspective on CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
February 24, 2022

Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022

Regulatory Press Release
Press Release
News
Read more
February 4, 2022

Elicera Therapeutics publishes annual report for 2021

Regulatory Press Release
Press Release
News
Read more
January 25, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory Press Release
Press Release
News
Read more
January 20, 2022

Interview and summary of 2021 in Biostock

Regulatory Press Release
Press Release
News
Read more
January 19, 2022

Elicera in Nordic Life Science - Vinnova grant

Regulatory Press Release
Press Release
News
Read more
January 18, 2022

Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process

Regulatory Press Release
Press Release
News
Read more
January 14, 2022

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Nordic Life Science News writes about Elicera's patent acquisition from Immunicum

Regulatory Press Release
Press Release
News
Read more
December 15, 2021

Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201

Regulatory Press Release
Press Release
News
Read more
November 18, 2021

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory Press Release
Press Release
News
Read more
November 9, 2021

Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy

Regulatory Press Release
Press Release
News
Read more
November 4, 2021

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 22, 2021

Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Nordic Life Science News

Regulatory Press Release
Press Release
News
Read more
October 5, 2021

Elicera Therapeutics announces participation in several industry and investor meetings in October and November

Regulatory Press Release
Press Release
News
Read more
September 13, 2021

Elicera Therapeutics will present the iTANK platform orally at ESGCT Collaborative Virtual Congress and PEGS Europe

Regulatory Press Release
Press Release
News
Read more
August 20, 2021

Interim Report Elicera Therapeutics AB January – June 2021

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics' board and management buy shares

Regulatory Press Release
Press Release
News
Read more
June 24, 2021

Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus

Regulatory Press Release
Press Release
News
Read more
June 10, 2021

Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 9, 2021

Elicera Therapeutics' new issue heavily oversubscribed

Regulatory Press Release
Press Release
News
Read more
June 4, 2021

Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 3, 2021

CEO-interview by Nyhetsbyrån Direkt

Regulatory Press Release
Press Release
News
Read more
May 31, 2021

Article in "Forskning och framsteg"

Regulatory Press Release
Press Release
News
Read more
May 24, 2021

Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
May 18, 2021

Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.

Regulatory Press Release
Press Release
News
Read more
May 17, 2021

Company presentation at "Aktiedagen Göteborg".

Regulatory Press Release
Press Release
News
Read more
April 27, 2021

Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
April 15, 2021

Biostock writes about Elicera and CAR T-cells

Regulatory Press Release
Press Release
News
Read more
March 22, 2021

Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera Therapeutics recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 8, 2021

Elicera Therapeutics invitation to company presentation (in Swedish)

Regulatory Press Release
Press Release
News
Read more
October 20, 2020

Daily Mail writes about Elicera

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing

Regulatory Press Release
Press Release
News
Read more
July 15, 2020

Immuno-Oncology News writes about Elicera's CAR T-cell program

Regulatory Press Release
Press Release
News
Read more
July 6, 2020

Financial Times writes about Elicera

Regulatory Press Release
Press Release
News
Read more
June 3, 2020

Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed

Regulatory Press Release
Press Release
News
Read more
April 23, 2020

Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100

Regulatory Press Release
Press Release
News
Read more
April 2, 2020

Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers

Regulatory Press Release
Press Release
News
Read more
January 10, 2020

Funding from the Sjöberg Foundation

Regulatory Press Release
Press Release
News
Read more
November 13, 2019

Funding by the Swedish Cancer Society

Regulatory Press Release
Press Release
News
Read more
March 2, 2018

Status update by Uppsala University on the clinical phase I/II-study in NET

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

The Medical Journal writes about a clinical study

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

Swedish Public Radio interviews Professor Magnus Essand

Regulatory Press Release
Press Release
News
Read more
October 27, 2014

Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)

Regulatory Press Release
Press Release
News
Read more
June 15, 2013

Successful crowdfunding

Regulatory Press Release
Press Release
News
Read more
February 21, 2024

Elicera Therapeutics publishes prospectus in connection with rights issue of units

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera invites to investor meetings on February 28[th] and 29[th] 2024

Regulatory Press Release
Press Release
News
Read more
February 13, 2024

Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023

Regulatory Press Release
Press Release
News
Read more
February 9, 2024

Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

Elicera’s Board of Directors proposes a rights issue of units of approximately SEK 64 million

Regulatory Press Release
Press Release
News
Read more
January 17, 2024

Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON

Regulatory Press Release
Press Release
News
Read more
January 9, 2024

Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application

Regulatory Press Release
Press Release
News
Read more
November 30, 2023

Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ)

Regulatory Press Release
Press Release
News
Read more
November 14, 2023

Elicera Therapeutics AB (publ) Interim Report January 1 – September 30, 2023

Regulatory Press Release
Press Release
News
Read more
October 31, 2023

Nomination Committee for Elicera therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
September 8, 2023

Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform

Regulatory Press Release
Press Release
News
Read more
August 29, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023

Regulatory Press Release
Press Release
News
Read more
August 10, 2023

Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program

Regulatory Press Release
Press Release
News
Read more
July 11, 2023

Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform

Regulatory Press Release
Press Release
News
Read more
May 16, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023

Regulatory Press Release
Press Release
News
Read more
April 28, 2023

Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study)

Regulatory Press Release
Press Release
News
Read more
April 17, 2023

Elicera Therapeutics publishes the annual report for 2022

Regulatory Press Release
Press Release
News
Read more
March 6, 2023

Erik Penser Bank initiates coverage on Elicera Therapeutics

Regulatory Press Release
Press Release
News
Read more
March 1, 2023

Elicera Therapeutics hires Erik Penser Bank as market maker

Regulatory Press Release
Press Release
News
Read more
February 17, 2023

Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022

Regulatory Press Release
Press Release
News
Read more
February 7, 2023

Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives

Regulatory Press Release
Press Release
News
Read more
January 26, 2023

Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 23, 2023

Elicera Therapeutics continues phase I/IIa study with oncolytic virus as planned, following safety review in cohort 3

Regulatory Press Release
Press Release
News
Read more
December 7, 2022

Elicera Therapeutics reports additional signals of clinical activity in patients treated for neuroendocrine tumors in the ELC-100 study at the Oncolytic Virotherapy Summit in Boston

Regulatory Press Release
Press Release
News
Read more
November 18, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2022

Regulatory Press Release
Press Release
News
Read more
November 16, 2022

Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support CAR T research

Regulatory Press Release
Press Release
News
Read more
November 3, 2022

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 18, 2022

Elicera Therapeutics enters first international collaboration involving the iTANK platform with a Spanish research institution

Regulatory Press Release
Press Release
News
Read more
October 12, 2022

Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy

Regulatory Press Release
Press Release
News
Read more
September 7, 2022

LifeScientist interviews Di Yu

Regulatory Press Release
Press Release
News
Read more
August 31, 2022

Oncology in Sweden publishes an article by Magnus Essand on Elicera's iTANK platform and upcoming clinical study

Regulatory Press Release
Press Release
News
Read more
August 22, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2022

Regulatory Press Release
Press Release
News
Read more
August 12, 2022

Elicera Therapeutics announces participation in several industry and partnering conferences

Regulatory Press Release
Press Release
News
Read more
June 2, 2022

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Interviews with Magnus Essand and Gunilla Enblad at SWECARNET's education day April 27

Regulatory Press Release
Press Release
News
Read more
April 26, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory Press Release
Press Release
News
Read more
April 10, 2022

Upsala Nya Tidning writes about Elicera's research and upcoming clinical studies

Regulatory Press Release
Press Release
News
Read more
April 7, 2022

Nordic Life Science News writes about the iTANK-publication

Regulatory Press Release
Press Release
News
Read more
April 6, 2022

Biostock makes a video interview with CSO, professor Magnus Essand, on the iTANK, publication.

Regulatory Press Release
Press Release
News
Read more
April 4, 2022

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
March 1, 2022

Elicera featured in Life Science Sweden's perspective on CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
February 24, 2022

Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022

Regulatory Press Release
Press Release
News
Read more
February 4, 2022

Elicera Therapeutics publishes annual report for 2021

Regulatory Press Release
Press Release
News
Read more
January 25, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory Press Release
Press Release
News
Read more
January 20, 2022

Interview and summary of 2021 in Biostock

Regulatory Press Release
Press Release
News
Read more
January 19, 2022

Elicera in Nordic Life Science - Vinnova grant

Regulatory Press Release
Press Release
News
Read more
January 18, 2022

Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process

Regulatory Press Release
Press Release
News
Read more
January 14, 2022

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Nordic Life Science News writes about Elicera's patent acquisition from Immunicum

Regulatory Press Release
Press Release
News
Read more
December 15, 2021

Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201

Regulatory Press Release
Press Release
News
Read more
November 18, 2021

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory Press Release
Press Release
News
Read more
November 9, 2021

Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy

Regulatory Press Release
Press Release
News
Read more
November 4, 2021

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 22, 2021

Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Nordic Life Science News

Regulatory Press Release
Press Release
News
Read more
October 5, 2021

Elicera Therapeutics announces participation in several industry and investor meetings in October and November

Regulatory Press Release
Press Release
News
Read more
September 13, 2021

Elicera Therapeutics will present the iTANK platform orally at ESGCT Collaborative Virtual Congress and PEGS Europe

Regulatory Press Release
Press Release
News
Read more
August 20, 2021

Interim Report Elicera Therapeutics AB January – June 2021

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics' board and management buy shares

Regulatory Press Release
Press Release
News
Read more
June 24, 2021

Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus

Regulatory Press Release
Press Release
News
Read more
June 10, 2021

Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 9, 2021

Elicera Therapeutics' new issue heavily oversubscribed

Regulatory Press Release
Press Release
News
Read more
June 4, 2021

Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 3, 2021

CEO-interview by Nyhetsbyrån Direkt

Regulatory Press Release
Press Release
News
Read more
May 31, 2021

Article in "Forskning och framsteg"

Regulatory Press Release
Press Release
News
Read more
May 24, 2021

Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
May 18, 2021

Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.

Regulatory Press Release
Press Release
News
Read more
May 17, 2021

Company presentation at "Aktiedagen Göteborg".

Regulatory Press Release
Press Release
News
Read more
April 27, 2021

Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
April 15, 2021

Biostock writes about Elicera and CAR T-cells

Regulatory Press Release
Press Release
News
Read more
March 22, 2021

Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera Therapeutics recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 8, 2021

Elicera Therapeutics invitation to company presentation (in Swedish)

Regulatory Press Release
Press Release
News
Read more
October 20, 2020

Daily Mail writes about Elicera

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing

Regulatory Press Release
Press Release
News
Read more
July 15, 2020

Immuno-Oncology News writes about Elicera's CAR T-cell program

Regulatory Press Release
Press Release
News
Read more
July 6, 2020

Financial Times writes about Elicera

Regulatory Press Release
Press Release
News
Read more
June 3, 2020

Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed

Regulatory Press Release
Press Release
News
Read more
April 23, 2020

Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100

Regulatory Press Release
Press Release
News
Read more
April 2, 2020

Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers

Regulatory Press Release
Press Release
News
Read more
January 10, 2020

Funding from the Sjöberg Foundation

Regulatory Press Release
Press Release
News
Read more
November 13, 2019

Funding by the Swedish Cancer Society

Regulatory Press Release
Press Release
News
Read more
March 2, 2018

Status update by Uppsala University on the clinical phase I/II-study in NET

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

The Medical Journal writes about a clinical study

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

Swedish Public Radio interviews Professor Magnus Essand

Regulatory Press Release
Press Release
News
Read more
October 27, 2014

Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)

Regulatory Press Release
Press Release
News
Read more
June 15, 2013

Successful crowdfunding

Regulatory Press Release
Press Release
News
Read more
February 21, 2024

Elicera Therapeutics publishes prospectus in connection with rights issue of units

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024

Regulatory Press Release
Press Release
News
Read more
February 16, 2024

Elicera invites to investor meetings on February 28[th] and 29[th] 2024

Regulatory Press Release
Press Release
News
Read more
February 13, 2024

Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023

Regulatory Press Release
Press Release
News
Read more
February 9, 2024

Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB

Regulatory Press Release
Press Release
News
Read more
January 18, 2024

Elicera’s Board of Directors proposes a rights issue of units of approximately SEK 64 million

Regulatory Press Release
Press Release
News
Read more
January 17, 2024

Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON

Regulatory Press Release
Press Release
News
Read more
January 9, 2024

Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research

Regulatory Press Release
Press Release
News
Read more
December 22, 2023

Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application

Regulatory Press Release
Press Release
News
Read more
November 30, 2023

Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ)

Regulatory Press Release
Press Release
News
Read more
November 14, 2023

Elicera Therapeutics AB (publ) Interim Report January 1 – September 30, 2023

Regulatory Press Release
Press Release
News
Read more
October 31, 2023

Nomination Committee for Elicera therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
September 8, 2023

Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform

Regulatory Press Release
Press Release
News
Read more
August 29, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023

Regulatory Press Release
Press Release
News
Read more
August 10, 2023

Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program

Regulatory Press Release
Press Release
News
Read more
July 11, 2023

Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform

Regulatory Press Release
Press Release
News
Read more
May 16, 2023

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023

Regulatory Press Release
Press Release
News
Read more
April 28, 2023

Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study)

Regulatory Press Release
Press Release
News
Read more
April 17, 2023

Elicera Therapeutics publishes the annual report for 2022

Regulatory Press Release
Press Release
News
Read more
March 6, 2023

Erik Penser Bank initiates coverage on Elicera Therapeutics

Regulatory Press Release
Press Release
News
Read more
March 1, 2023

Elicera Therapeutics hires Erik Penser Bank as market maker

Regulatory Press Release
Press Release
News
Read more
February 17, 2023

Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022

Regulatory Press Release
Press Release
News
Read more
February 7, 2023

Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives

Regulatory Press Release
Press Release
News
Read more
January 26, 2023

Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma

Regulatory Press Release
Press Release
News
Read more
January 23, 2023

Elicera Therapeutics continues phase I/IIa study with oncolytic virus as planned, following safety review in cohort 3

Regulatory Press Release
Press Release
News
Read more
December 7, 2022

Elicera Therapeutics reports additional signals of clinical activity in patients treated for neuroendocrine tumors in the ELC-100 study at the Oncolytic Virotherapy Summit in Boston

Regulatory Press Release
Press Release
News
Read more
November 18, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2022

Regulatory Press Release
Press Release
News
Read more
November 16, 2022

Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support CAR T research

Regulatory Press Release
Press Release
News
Read more
November 3, 2022

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 18, 2022

Elicera Therapeutics enters first international collaboration involving the iTANK platform with a Spanish research institution

Regulatory Press Release
Press Release
News
Read more
October 12, 2022

Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy

Regulatory Press Release
Press Release
News
Read more
September 7, 2022

LifeScientist interviews Di Yu

Regulatory Press Release
Press Release
News
Read more
August 31, 2022

Oncology in Sweden publishes an article by Magnus Essand on Elicera's iTANK platform and upcoming clinical study

Regulatory Press Release
Press Release
News
Read more
August 22, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2022

Regulatory Press Release
Press Release
News
Read more
August 12, 2022

Elicera Therapeutics announces participation in several industry and partnering conferences

Regulatory Press Release
Press Release
News
Read more
June 2, 2022

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Regulatory Press Release
Press Release
News
Read more
April 27, 2022

Interviews with Magnus Essand and Gunilla Enblad at SWECARNET's education day April 27

Regulatory Press Release
Press Release
News
Read more
April 26, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory Press Release
Press Release
News
Read more
April 10, 2022

Upsala Nya Tidning writes about Elicera's research and upcoming clinical studies

Regulatory Press Release
Press Release
News
Read more
April 7, 2022

Nordic Life Science News writes about the iTANK-publication

Regulatory Press Release
Press Release
News
Read more
April 6, 2022

Biostock makes a video interview with CSO, professor Magnus Essand, on the iTANK, publication.

Regulatory Press Release
Press Release
News
Read more
April 4, 2022

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
March 1, 2022

Elicera featured in Life Science Sweden's perspective on CAR T-cell therapies

Regulatory Press Release
Press Release
News
Read more
February 24, 2022

Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022

Regulatory Press Release
Press Release
News
Read more
February 4, 2022

Elicera Therapeutics publishes annual report for 2021

Regulatory Press Release
Press Release
News
Read more
January 25, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory Press Release
Press Release
News
Read more
January 20, 2022

Interview and summary of 2021 in Biostock

Regulatory Press Release
Press Release
News
Read more
January 19, 2022

Elicera in Nordic Life Science - Vinnova grant

Regulatory Press Release
Press Release
News
Read more
January 18, 2022

Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process

Regulatory Press Release
Press Release
News
Read more
January 14, 2022

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum

Regulatory Press Release
Press Release
News
Read more
January 5, 2022

Nordic Life Science News writes about Elicera's patent acquisition from Immunicum

Regulatory Press Release
Press Release
News
Read more
December 15, 2021

Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201

Regulatory Press Release
Press Release
News
Read more
November 18, 2021

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory Press Release
Press Release
News
Read more
November 9, 2021

Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy

Regulatory Press Release
Press Release
News
Read more
November 4, 2021

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Press Release
News
Read more
October 22, 2021

Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory Press Release
Press Release
News
Read more
October 20, 2021

Nordic Life Science News

Regulatory Press Release
Press Release
News
Read more
October 5, 2021

Elicera Therapeutics announces participation in several industry and investor meetings in October and November

Regulatory Press Release
Press Release
News
Read more
September 13, 2021

Elicera Therapeutics will present the iTANK platform orally at ESGCT Collaborative Virtual Congress and PEGS Europe

Regulatory Press Release
Press Release
News
Read more
August 20, 2021

Interim Report Elicera Therapeutics AB January – June 2021

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market

Regulatory Press Release
Press Release
News
Read more
July 5, 2021

Elicera Therapeutics' board and management buy shares

Regulatory Press Release
Press Release
News
Read more
June 24, 2021

Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus

Regulatory Press Release
Press Release
News
Read more
June 10, 2021

Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 9, 2021

Elicera Therapeutics' new issue heavily oversubscribed

Regulatory Press Release
Press Release
News
Read more
June 4, 2021

Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
June 3, 2021

CEO-interview by Nyhetsbyrån Direkt

Regulatory Press Release
Press Release
News
Read more
May 31, 2021

Article in "Forskning och framsteg"

Regulatory Press Release
Press Release
News
Read more
May 24, 2021

Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory Press Release
Press Release
News
Read more
May 18, 2021

Eliceras CEO, Jamal El-Mosleh, recognized on In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors.

Regulatory Press Release
Press Release
News
Read more
May 17, 2021

Company presentation at "Aktiedagen Göteborg".

Regulatory Press Release
Press Release
News
Read more
April 27, 2021

Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
April 15, 2021

Biostock writes about Elicera and CAR T-cells

Regulatory Press Release
Press Release
News
Read more
March 22, 2021

Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera Therapeutics recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 11, 2021

Elicera recruits CFO

Regulatory Press Release
Press Release
News
Read more
January 8, 2021

Elicera Therapeutics invitation to company presentation (in Swedish)

Regulatory Press Release
Press Release
News
Read more
October 20, 2020

Daily Mail writes about Elicera

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

Regulatory Press Release
Press Release
News
Read more
October 5, 2020

Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing

Regulatory Press Release
Press Release
News
Read more
July 15, 2020

Immuno-Oncology News writes about Elicera's CAR T-cell program

Regulatory Press Release
Press Release
News
Read more
July 6, 2020

Financial Times writes about Elicera

Regulatory Press Release
Press Release
News
Read more
June 3, 2020

Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed

Regulatory Press Release
Press Release
News
Read more
April 23, 2020

Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100

Regulatory Press Release
Press Release
News
Read more
April 2, 2020

Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers

Regulatory Press Release
Press Release
News
Read more
January 10, 2020

Funding from the Sjöberg Foundation

Regulatory Press Release
Press Release
News
Read more
November 13, 2019

Funding by the Swedish Cancer Society

Regulatory Press Release
Press Release
News
Read more
March 2, 2018

Status update by Uppsala University on the clinical phase I/II-study in NET

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

The Medical Journal writes about a clinical study

Regulatory Press Release
Press Release
News
Read more
December 12, 2016

Swedish Public Radio interviews Professor Magnus Essand

Regulatory Press Release
Press Release
News
Read more
October 27, 2014

Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)

Regulatory Press Release
Press Release
News
Read more
June 15, 2013

Successful crowdfunding

Regulatory Press Release
Press Release
News
Read more

Sign up for Press Releases

By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.